miR-21对HepG2细胞增殖、凋亡和细胞周期的影响*

doi:10.3969/j.issn.1672-5069.2019.01.007

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (1): 21-24.doi: 10.3969/j.issn.1672-5069.2019.01.007

miR-21对HepG2细胞增殖、凋亡和细胞周期的影响^*

张小三, 张一鸣, 杨树军, 戚春辉, 刘凯, 赵燕

450008 郑州市郑州大学附属河南省肿瘤医院内科（张小三,张一鸣,杨树军,赵燕）; 郑州市第七人民医院儿科（戚春辉）; 焦作市第二人民医院肿瘤内科二区（刘凯）

收稿日期:2018-05-20 出版日期:2019-01-10 发布日期:2019-01-16
通讯作者: 赵燕,E-mail:hyymaq@163.com
作者简介:张小三,男,37岁,医学博士,主治医师。主要从事实体肿瘤的内科治疗学研究。E-mail:jhkikc@163.com
基金资助:
*河南省自然科学研究计划项目(编号:201310471055)

Impact of miR-21 on proliferation and apoptosis in HepG2 cells in vitro

Zhang Xiaosan, Zhang Yiming, Yang Shujun, et al.

Department of Internal Medicine,Provincial Tumor Hospital,Affiliated to Zhengzhou University,Zhengzhou 450008,Henan Province,China

Received:2018-05-20 Online:2019-01-10 Published:2019-01-16

摘要/Abstract

摘要： 目的研究miR-21对HepG2 细胞增殖和凋亡的影响并探讨其可能的分子机制。方法体外培养HepG2细胞,并将细胞分为增强组、抑制组和对照组,分别给予Lipofectamine 2000和Hsa-miR-21 mimics （50 nm/L）、Lipofectamine 2000和Has-miR-21 inhibitor（100 nm/L）转染或者给予Lipofectamine 2000处理干预。采用Western blot法检测B细胞异位基因2（BTG2）蛋白表达,采用CCK-8法检测细胞增殖,使用流式细胞术（FCM）检测细胞周期和凋亡变化。结果增强组细胞BTG2 蛋白表达水平最低,抑制组细胞BTG2 蛋白表达水平最高,对照组细胞BTG2蛋白表达水平强于增强组而低于抑制组,组间差异比较有统计学意义（P<0.05）;抑制组细胞增殖率较增强组和对照组明显降低（P<0.05）,增强组较对照组明显增强（P<0.05）;与增强组或对照组比,抑制组细胞周期S期明显减少（P<0.05）,而G2期则明显增多（P<0.05）,与对照组比,增强组S期明显增加,而G2期明显较少（P<0.05）;与增强组和对照组比,抑制组细胞凋亡率显著增加（P<0.05）,而与对照组比,增强组细胞凋亡率显著减少（P<0.05）。结论 miR-21可能通过直接靶向调控BTG2表达而影响HepG2细胞的生长,可能成为干预肝癌生长的新途径。

关键词: HepG2细胞, miR-21, B细胞异位基因2蛋白, 增殖, 凋亡, 体外

Abstract: Objective To investigate the impact of miR-21 on proliferation and apoptosis in HepG2 cells in vitro. Methods HepG2 cells were divided into three groups,intervened respectively by Lipofectamine 2000/Hsa-miR-21 mimics（enhancement）,Lipofectamine 2000/Has-miR-21 inhibitor（inhibition） and Lipofectamine 2000（control）. The expression of B-cell translocation gene 2（BTG2） protein was detected by Western blot,cell proliferation by CCK-8,and cell cycle and apoptosis by flow cytometry（FCM）. Results The expression of BTG2 in enhancement group decreased obviously and it increased in inhibition group,which were significantly different as compared to that in the control（P<0.05）;the proliferation of HepG2 cells in inhibition group decreased significantly as compared to those in enhancement or control cell（P<0.05）,while it increased obviously as compared to that in the control（P<0.05）;the proportion of S phase cells in inhibition group decreased markedly as compared to those in the enhancement or control （P<0.05）,while G2 phase cells obviously increased （P<0.05）,and S phase cells in enhancement increased and G2 cells decreased as compared to that in the control（P<0.05）;the apoptosis in inhibition obviously increased as compared to those in the enhancement or control（P<0.05）,while it in enhancement significantly decreased as compared to that in the control（P<0.05）. Conclusion MiR-21 might play an important role in hepatocarcinogenesis by intervention of BTG2 expression,which might be a new approach to deal with hepatocellular carcinoma.

Key words: HepG2 cells, miR-21, B-cell translocation gene 2 Proliferation, Apoptosis, In vitro

张小三, 张一鸣, 杨树军, 戚春辉, 刘凯, 赵燕. miR-21对HepG2细胞增殖、凋亡和细胞周期的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 21-24.

Zhang Xiaosan, Zhang Yiming, Yang Shujun, et al.. Impact of miR-21 on proliferation and apoptosis in HepG2 cells in vitro[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 21-24.

参考文献

[1] Akinyemiju T,Abera S,Ahmed M,et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global,regional,and national level:Results from the global burden of disease study 2015. Jama Oncol,2018,3(12):1683-1691.
[2] Zuo T,Zheng R,Zeng H,et al.Analysis of liver cancer incidence and trend in China. Chin J Oncol,2015,37(9):691-696.
[3] Aerts M,Benteyn D,van Vlierberghe H,et al. Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol,2016,22(1):253-261.
[4] Yang N,Ekanem NR,Sakyi CA,et al.Hepatocellular carcinoma and microRNA:new perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev,2015,81:62-74.
[5] Dalton-Fitzgerald E,Tiro J,Kandunoori P,et al.Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol,2015,13(4):791-798.
[6] 裴丽玲,李建生,任维华. miRNAs 与肝细胞癌发生研究进展. 实用肝脏病杂志,2014,17(2):221-224.
[7] D'Anzeo M,Faloppi L,Scartozzi M,et al. The role of micro-RNAs in hepatocellular carcinoma:from molecular biology to treatment. Molecules,2014,19(5):6393-6406.
[8] Ullah S,John P,Bhatti A.MicroRNAs with a role in gene regulation and in human diseases. Mol Biol Rep,2014,41(1):225-232.
[9] Lujambio A,Lowe SW.The microcosmos of cancer. Nature,2012,482(7385):347-355.
[10] Borel F,Konstantinova P,Jansen P L M. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol,2012,56(6):1371-1383.
[11] Hashemi ZS,Khalili S,Moghadam MF,et al.Lung cancer and miRNAs:a possible remedy for anti-metastatic,therapeutic and diagnostic applications. Expert Rev Respir Med,2017,11(2):147-157.
[12] Deb B,Uddin A,Chakraborty S. miRNAs and ovarian cancer: An overview. J Cell Physiol,2018,233(5):3846-3854.
[13] Nair VS,Maeda LS,Ioannidis JP.Clinical outcome prediction by micro RNAs in human cancer:a systematic review. J Natl Cancer Inst,2012,104(7):528-540.
[14] Ross SA,Davis CD.Micro RNA,nutrition,and cancer prevention. Adv Nutr,2011,2(6):472-485.
[15] Li L,Zhou L,Li Y,et al.MicroRNA-21 stimulates gastric cancer growth and invasion by inhibiting the tumor suppressor effects of programmed cell death protein 4 and phosphatase and tensin homolog. J Buon,2014,19(1):228-236.
[16] Leong H,Bruce A,Gregory T,et al.MicroRNA-21 as a potential colon and rectal cancer biomarker. World J Gastroenterol,2013,19(34):5615-5621.
[17] Liu J,Zhu H,Yang X,et al.MicroRNA-21 is a novel promising target in cancer radiation therapy. Tumour Biol,2014,35(5):3975-3979.
[18] Shen H,Zhu F,Liu J,et al.Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. Plos One,2014,9(7):e103305.

miR-21对HepG2细胞增殖、凋亡和细胞周期的影响^*

Impact of miR-21 on proliferation and apoptosis in HepG2 cells in vitro

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	徐飞, 李伟荣. 黄芪甲苷对CCL₄所致肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 808-811.
[3]	蔡美洪, 王绮夏, 马雄. 肝内胆管缺失的病理生理学研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 620-623.
[4]	赵芳芳, 翟永贞, 冯国和. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者疗效及安全性分析[J]. 实用肝脏病杂志, 2019, 22(5): 700-703.
[5]	张莹, 王洪岩, 迟程, 徐有青. LPS诱导的HepG2细胞NOTCH与LPS-TLR4-NF-κB炎症信号通路的“会话”研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 470-473.
[6]	王爽, 许坚吉, 刘晓霓, 陈德喜. 荧光素酶生物发光报告体系的优化及在肝癌荷瘤裸鼠模型中的应用^*[J]. 实用肝脏病杂志, 2019, 22(4): 482-485.
[7]	曹白鸽,刘冲霄,陈源文,董艳. IL-6上调SCD1表达对HepG2细胞脂质合成功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(2): 172-175.
[8]	郭丽平, 张成宏, 宁宝烁, 许敏, 徐贝贝, 王雪, 李异玲. 一种新生大鼠肝细胞分离改良方法的建立^*[J]. 实用肝脏病杂志, 2019, 22(1): 17-20.
[9]	姜哲, 舒敏, 王媛媛, 朴莲淑. miR-363靶向调控E2F3表达影响HepG2细胞增殖和凋亡研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 825-828.
[10]	徐溪, 党引利, 吴朔. HCV感染相关干扰素L4真核表达载体的构建与表达[J]. 实用肝脏病杂志, 2018, 21(6): 833-836.
[11]	李俊峰, 郑素军, 刘霜, 任锋, 陈煜, 段钟平. 葡萄糖神经酰胺葡萄糖基转移酶siRNA对7702肝细胞增殖的影响及机制研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 697-700.
[12]	高翔, 尚双艳. 复方鳖甲软肝片对二乙基亚硝胺所致原发性肝癌大鼠肝组织PCNA和α-SMA表达的影响^*[J]. 实用肝脏病杂志, 2018, 21(4): 553-556.
[13]	周达, 王晶, 李冰航, 孙超, 陈源文, 范建高. 脯氨酰寡肽酶抑制剂体外对肝星状细胞凋亡、增殖和肝纤维化相关基因表达的影响*[J]. 实用肝脏病杂志, 2018, 21(3): 388-392.
[14]	李文姣, 曹海超, 马澜婧, 张松, 丁美玲, 张浩浩, 聂勇战. 敲减CCAAT/增强子结合蛋白α通过增加O-GlcNAc糖基化水平促进肝癌细胞体外增殖*[J]. 实用肝脏病杂志, 2018, 21(3): 393-396.
[15]	张永婷, 朱传龙, 李军, 章莉莉. c-Met基因过表达脐带间充质干细胞株的构建*[J]. 实用肝脏病杂志, 2018, 21(3): 397-400.